Cediranib for alveolar soft part sarcoma: a randomised study in relation to clinical practice

Lancet Oncol. 2019 Jul;20(7):901-903. doi: 10.1016/S1470-2045(19)30324-9. Epub 2019 May 31.

Authors

Sandro Pasquali¹, Silvia Stacchiotti²

Affiliations

¹ Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy. Electronic address: sandro.pasquali@istitutotumori.mi.it.
² Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy.

PMID: 31160250
DOI: 10.1016/S1470-2045(19)30324-9

No abstract available

Publication types

Comment

MeSH terms

Double-Blind Method
Humans
Quinazolines
Sarcoma, Alveolar Soft Part*

Substances

Quinazolines
cediranib